Skip to main content
OpenTrials
Completed

NCT Number: NCT01092780

Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010)

This is a study of the safety and efficacy of MK-7288 for the treatment of excessive daytime sleepiness (EDS) in participants with obstructive sleep apnea (OSA)/hypopnea syndrome (HS) who are compliant with effective nasal continuous positive airway pressure (nCPAP) therapy. The goal of this study is to determine the effect of MK-7288 after single dose administration on promoting wakefulness as measured by sleep latency on Maintenance of Wakefulness Tests, and on driving performance as measured by standard deviation of lane position in simulated driving (country vigilance driving).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Apnea, Sleep Apnea Dyssomnias Nervous System Diseases Respiration Disorders Respiratory Tract Diseases Sleep Apnea Syndromes Sleep Disorders, Intrinsic Sleep Wake Disorders

Age range

18 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female participants are of non-child-bearing potential.
  • Male participants who have female partner(s) of child-bearing potential must agree to use a medically acceptable method of contraception during the study.
  • Participant has an International Classification of Sleep Disorders diagnosis of Obstructive Sleep Apnea/Hypopnea Syndrome.
  • Participant has excessive daytime sleepiness.
  • Participant has been using nCPAP treatment for at least 2 months.
  • Participant reported total sleep time of >6 hours on at least 4 out of 7 nights each week
  • Participant is willing to stay at the sleep laboratory for 5 overnight stays.
  • Participant is willing to limit caffeine and alcohol consumption during the study.
  • Participant has a valid driver's license in the past 5 years and has had at least 1 year of driving experience within the past 3 years.
  • Participant's regular bedtime is between 9:00 p.m. and 12:00 a.m.

Exclusion criteria

  • Participant has a history of cancer.
  • Participant has any history of a significant neurological disorder.
  • Participant has moderate or severe persistent asthma.
  • Participant has a history of any of the following sleep disorders: narcolepsy, primary insomnia, Circadian rhythm sleep disorder, shift work sleep disorder, parasomnia including nightmare disorder, sleep terror disorder, rapid eye movement (REM) behavioral disorder, and sleepwalking disorder, periodic limb movement disorder, or restless leg syndrome.
  • Participant consumes more than 10 cigarettes a day or routinely smokes during the night.
  • Participant, in the opinion of the investigator, has a history or current evidence of any condition, therapy, lab abnormality or circumstances that might confound the results of the study, or interfere with participation for the full duration of the study.

Treatment and study plan

MK-7288

Drug

one or two 10 mg capsules, orally, single dose

Placebo to MK-7288

Drug

one or two capsules, orally, single dose

Modafinil

Drug

two 100 mg tablets, orally, single dose

Other names: PROVIGIL®

Placebo to modafinil

Drug

two 100 mg tablets, orally, single dose

Primary outcomes

  1. Mean Sleep Latency Score on the Maintenance of Wakefulness Test (MWT) for Participants Taking MK-7288 Versus Placebo

    Time frame: 1, 3, 5 and 7 hours post dose

    Study drug was administered at 08:00. MWT, an objective measure of the participant's ability to maintain wakefulness, was administered at 09:00, 11:00, 13:00 and 15:00. A least squares (LS) mean of the 4 MWTs performed at 09:00, 11:00, 13:00 and 15:00 was calculated. Latency for each MWT is defined as the time to onset of the first 16 continuous seconds of any stage of sleep; if no sleep has been observed according to these rules, then the latency is defined as 30 minutes. A higher MWT value is considered a better outcome.

  2. Mean Score on Standard Deviation of Lane Position (SDLP) Driving Test for Participants Taking MK-7288 Versus Placebo

    Time frame: 2, 4 and 6 hours post dose

    Study drug was administered at 08:00. Driving performance was measured by the SDLP test which is a 45-minute driving simulation country vigilance test and was performed by participants at 10:00, 12:00 and 14:00. An LS mean of the 2 SDLP driving test results performed at 10:00 and 14:00 was calculated. A lower value is considered a better outcome.

  3. Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs)

    Time frame: Up to 36 days

    An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition which is temporally associated with the use of the study drug, is also an AE.

Secondary outcomes

  1. Mean Sleep Latency Score on the MWT for Participants Taking MK-7288 Versus Modafinil

    Time frame: 1, 3, 5 and 7 hours post dose

    Study drug was administered at 08:00. MWT, an objective measure of the participant's ability to maintain wakefulness, was administered at 09:00, 11:00, 13:00 and 15:00. A least squares (LS) mean of the 4 MWTs performed at 09:00, 11:00, 13:00 and 15:00 was calculated. Latency for each MWT is defined as the time to onset of the first 16 continuous seconds of any stage of sleep; if no sleep has been observed according to these rules, then the latency is defined as 30 minutes. A higher MWT value is considered a better outcome.

  2. Mean Sleep Latency Score on the MWT for Participants Taking Modafinil Versus Placebo

    Time frame: 1, 3, 5 and 7 hours post dose

    Study drug was administered at 08:00. MWT, an objective measure of the participant's ability to maintain wakefulness, was administered at 09:00, 11:00, 13:00 and 15:00. A least squares (LS) mean of the 4 MWTs performed at 09:00, 11:00, 13:00 and 15:00 was calculated. Latency for each MWT is defined as the time to onset of the first 16 continuous seconds of any stage of sleep; if no sleep has been observed according to these rules, then the latency is defined as 30 minutes. A higher MWT value is considered a better outcome.

  3. Mean Score on SDLP Driving Test for Participants Taking Modafinil Versus Placebo

    Time frame: 2, 4 and 6 hours post dose

    Study drug was administered at 08:00. Driving performance was measured by the SDLP test which is a 45-minute driving simulation country vigilance test and was performed by participants at 10:00, 12:00 and 14:00. An LS mean of the 2 SDLP driving test results performed at 10:00 and 14:00 was calculated. A lower value is considered a better outcome.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

An Active-Comparator Controlled Single Dose Study to Evaluate the Pharmacodynamics/Efficacy of MK-7288 in Sleep Apnea Patients

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Mar 25, 2010
Registry last updated
Nov 8, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.